Evidence map›Paper›PMID 38268604›Full record

ArticleHeliyon2024

A label free chemoproteomic-based platform to disclose cannabidiol molecular mechanism of action on chronic myelogenous leukemia cancer cells.

Sara Ceccacci, Lorenzo Corsi, Lucio Spinelli, Clarissa Caroli, Matilde Marani, Lisa Anceschi, Matteo Mozzicafreddo, Federica Pellati, Maria Chiara Monti

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Sara CeccacciDepartment of Pharmacy, Università di Salerno, Via Giovanni Paolo II, 84084, Fisciano, Italy.
Lorenzo CorsiDepartment of Life Sciences, University of Modena and Reggio Emilia, Via G. Campi 103/287, 41125, Modena, Italy.
Lucio SpinelliDepartment of Pharmacy, Università di Salerno, Via Giovanni Paolo II, 84084, Fisciano, Italy.
Clarissa CaroliDepartment of Life Sciences, University of Modena and Reggio Emilia, Via G. Campi 103/287, 41125, Modena, Italy.
Matilde MaraniDepartment of Life Sciences, University of Modena and Reggio Emilia, Via G. Campi 103/287, 41125, Modena, Italy.
Lisa AnceschiDepartment of Life Sciences, University of Modena and Reggio Emilia, Via G. Campi 103/287, 41125, Modena, Italy.
Matteo MozzicafreddoDepartment of Clinical and Molecular Sciences, Università Politecnica delle Marche, 60126, Ancona, Italy.
Federica PellatiDepartment of Life Sciences, University of Modena and Reggio Emilia, Via G. Campi 103/287, 41125, Modena, Italy.
Maria Chiara MontiDepartment of Pharmacy, Università di Salerno, Via Giovanni Paolo II, 84084, Fisciano, Italy.
University of Modena and Reggio Emilia · ITUniversity of Salerno · ITMarche Polytechnic University · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The discovery of the interactome of cannabidiol (CBD), a non-psychoactive cannabinoid from

Indexed as

CannabidiolChemo-proteomicsChronic myelogenous leukemiaDrug Affinity Responsive Target StabilityLimited proteolysisMass spectrometryMulti-target activity

Identifiers

PMID38268604
PMCPMC10806336
OpenAlexW4390607428

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.